Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
05:57pm, Wednesday, 28'th Feb 2024
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and
Mesoblast Financial Results and Corporate Update Webcast
07:00am, Monday, 26'th Feb 2024
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation
NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States F
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
09:13pm, Tuesday, 30'th Jan 2024
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for th
Top 4 Health Care Stocks That May Explode This Month - Mesoblast (NASDAQ:MESO), Humana (NYSE:HUM)
07:03am, Friday, 26'th Jan 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
12:31pm, Friday, 19'th Jan 2024
Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.
REVASCOR Increases Size of Left Heart Chamber and Improves Surgical Outcomes in Children with Hypoplastic Left Heart Syndrome: Results Published in Journal of Thoracic and Cardiovascular Surgery Open
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:18am, Friday, 05'th Jan 2024
Mesoblast Limited (MESO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in
Mesoblast Has Major Hurdles
06:37pm, Friday, 22'nd Dec 2023
The FDA has rejected Mesoblast's cell therapy candidate for pediatric acute graft versus host disease, causing the stock to decline. Mesoblast is an old company located in Australia, which may impact
5 Stocks to Ride the Santa Claus Rally
11:17am, Thursday, 21'st Dec 2023
Mesoblast (MESO), Coinbase (COIN), Western Gas (WES), JAKKS Pacific (JAKK), and Brinker International (EAT) have the potential to outperform in the seven-day period.
NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for or
Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
10:31am, Thursday, 23'rd Nov 2023
Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
06:32pm, Tuesday, 21'st Nov 2023
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the Blood and Marro
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
08:04pm, Monday, 30'th Oct 2023
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for th
Mesoblast Limited (MESO) Q4 2023 Earnings Call Transcript
10:25pm, Wednesday, 30'th Aug 2023
Mesoblast Limited (NASDAQ:MESO ) Q4 2023 Results Conference Call August 30, 2023 6:30 PM ET Company Participants Dr. Silviu Itescu - Chief Executive Officer Dr. Eric Rose - Chief Medical Officer Andre
